Onconetix Stock Price Patterns
| ONCO Stock | USD 1.85 0.34 22.52% |
Momentum 40
Sell Extended
Oversold | Overbought |
Wall Street Target Price 9 | Quarterly Revenue Growth (0.25) |
Using Onconetix hype-based prediction, you can estimate the value of Onconetix from the perspective of Onconetix response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Onconetix to buy its stock at a price that has no basis in reality. In that case, they are not buying Onconetix because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Onconetix after-hype prediction price | USD 1.84 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Onconetix | Build AI portfolio with Onconetix Stock |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Onconetix's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Onconetix After-Hype Price Density Analysis
As far as predicting the price of Onconetix at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Onconetix or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Onconetix, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Onconetix Estimiated After-Hype Price Volatility
In the context of predicting Onconetix's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Onconetix's historical news coverage. Onconetix's after-hype downside and upside margins for the prediction period are 0.09 and 9.92, respectively. We have considered Onconetix's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Onconetix is very risky at this time. Analysis and calculation of next after-hype price of Onconetix is based on 3 months time horizon.
Onconetix Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Onconetix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Onconetix backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Onconetix, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.05 | 8.08 | 0.01 | 0.00 | 7 Events / Month | 6 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.85 | 1.84 | 0.54 |
|
Onconetix Hype Timeline
Onconetix is now traded for 1.85. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of 0.0. Onconetix is forecasted to decline in value after the next headline, with the price expected to drop to 1.84. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.54%, whereas the daily expected return is now at -0.05%. The volatility of related hype on Onconetix is about 53866.67%, with the expected price after the next announcement by competition of 1.85. About 20.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Onconetix recorded earning per share (EPS) of 1229.73. The entity had not issued any dividends in recent years. The firm had 1:85 split on the 13th of June 2025. Given the investment horizon of 90 days the next forecasted press release will be in about 7 days. Check out Onconetix Basic Forecasting Models to cross-verify your projections.Onconetix Related Hype Analysis
Having access to credible news sources related to Onconetix's direct competition is more important than ever and may enhance your ability to predict Onconetix's future price movements. Getting to know how Onconetix's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Onconetix may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| JSPR | Jasper Therapeutics | 0.17 | 8 per month | 0.00 | (0.11) | 7.19 | (8.14) | 31.75 | |
| AZTR | Azitra Inc | (0.09) | 16 per month | 0.00 | (0.16) | 6.90 | (11.11) | 36.11 | |
| REVB | Revelation Biosciences | 0.19 | 8 per month | 0.00 | (0.24) | 6.84 | (10.16) | 35.57 | |
| SCNI | Scinai Immunotherapeutics | 0.05 | 7 per month | 0.00 | (0.06) | 11.65 | (9.09) | 38.82 | |
| SPRC | Scisparc | (0.01) | 8 per month | 0.00 | (0.37) | 5.00 | (12.50) | 30.69 | |
| INDP | Indaptus Therapeutics | (0.09) | 8 per month | 0.00 | (0.04) | 16.13 | (13.41) | 51.64 | |
| ENVB | Enveric Biosciences | (0.02) | 7 per month | 0.00 | (0.08) | 10.37 | (11.42) | 121.83 | |
| SLXN | Biomotion Sciences Ordinary | (0.04) | 5 per month | 0.00 | (0.11) | 15.09 | (9.15) | 37.24 | |
| PTIX | Protagenic Therapeutics | 0.01 | 5 per month | 0.00 | (0.20) | 14.81 | (18.37) | 58.73 | |
| SLRX | Salarius Pharmaceuticals | (0.02) | 6 per month | 0.00 | (0.19) | 16.00 | (16.92) | 61.05 |
Onconetix Additional Predictive Modules
Most predictive techniques to examine Onconetix price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Onconetix using various technical indicators. When you analyze Onconetix charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Onconetix Predictive Indicators
The successful prediction of Onconetix stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Onconetix, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Onconetix based on analysis of Onconetix hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Onconetix's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Onconetix's related companies. | 2010 | 2025 | 2026 (projected) | Dividend Yield | 0.12 | 0.11 | 0.096 | Price To Sales Ratio | 57.94 | 0.79 | 0.75 |
Pair Trading with Onconetix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onconetix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will appreciate offsetting losses from the drop in the long position's value.Moving together with Onconetix Stock
Moving against Onconetix Stock
| 0.85 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.65 | ENGN | enGene Holdings Common | PairCorr |
| 0.6 | DSGN | Design Therapeutics | PairCorr |
| 0.51 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.49 | 63E | ONWARD MEDICAL BV | PairCorr |
The ability to find closely correlated positions to Onconetix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onconetix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onconetix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onconetix to buy it.
The correlation of Onconetix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onconetix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onconetix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onconetix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Onconetix Basic Forecasting Models to cross-verify your projections. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Will Biotechnology sector continue expanding? Could Onconetix diversify its offerings? Factors like these will boost the valuation of Onconetix. Anticipated expansion of Onconetix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Onconetix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 1.2 K | Revenue Per Share | Quarterly Revenue Growth (0.25) | Return On Assets | Return On Equity |
Understanding Onconetix requires distinguishing between market price and book value, where the latter reflects Onconetix's accounting equity. The concept of intrinsic value - what Onconetix's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Onconetix's price substantially above or below its fundamental value.
It's important to distinguish between Onconetix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Onconetix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Onconetix's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.